FDAnews Drug Daily Bulletin

STRESSGEN BIOTECHNOLOGIES ANNOUNCES THIRD QUARTER 2005 FINANCIAL RESULTS

Nov. 9, 2005
A A

Stressgen Biotechnologies ("The Company") (TSX: SSB) announced today financial results for the third quarter ended September 30, 2005. All amounts, unless specified otherwise, are in Canadian dollars. Stressgen reported a net loss from continuing operations of $5.7 million, or $0.08 (US$0.07) per share, for the three months ended September 30, 2005, compared to a net loss from continuing operations of $8.4 million, or $0.12 (US$0.09) per share, for the same period in 2004.
PR Newswire